Evidence review
NAD+ Therapy: Strong Biology, Weak Clinical Evidence
NAD+ is a genuinely important coenzyme and its decline with age is well documented. What does not follow is that supplementing it produces the clinical benefits marketed
NAD+ is a genuinely important coenzyme and its decline with age is well documented. What does not follow is that supplementing it produces the clinical benefits marketed for it. Human trials of NAD+ precursors have reliably raised blood NAD+ levels and have not reliably produced functional benefit.
The biology is real
NAD+ is a coenzyme central to cellular energy metabolism and to the function of sirtuins and PARPs. Tissue NAD+ declines with age across multiple species, and restoring it in animal models produces measurable effects on metabolic and mitochondrial function.
None of that is controversial, and it is why the field attracted serious research investment rather than only commercial interest.
Where the evidence stops
Human trials of NAD+ precursors — nicotinamide riboside and nicotinamide mononucleotide — have consistently shown that oral supplementation raises circulating NAD+ levels. That is a pharmacokinetic finding: the compound gets in and does what it is supposed to biochemically.
What those trials have generally not shown is corresponding clinical benefit on hard endpoints. Improvements in muscle function, insulin sensitivity, cognitive performance and biomarkers of ageing have been inconsistent, small, or absent depending on the trial and population.
That pattern — target engagement without clinical benefit — is one of the most common outcomes in translational research, and it is the single most important thing to understand about this category.
The IV question
NAD+ administered intravenously is marketed at a substantial premium over oral precursors. The rationale offered is bioavailability.
What is missing is any demonstration that raising NAD+ faster or higher produces outcomes that oral precursors do not. If the limiting factor were blood levels, oral trials that successfully raised blood levels should have produced benefit. They largely did not.
Infusions also carry the ordinary risks of intravenous access, and the reported experience during infusion is frequently unpleasant at higher rates.
How to read a NAD+ claim
- Does the cited study measure NAD+ levels, or does it measure an outcome a patient would notice?
- Is it a human randomised trial, or animal work, or an uncontrolled series?
- What was the population, and does it resemble you?
- Is the effect size clinically meaningful, or statistically detectable but small?
Most marketing in this category relies on the first question being answered "levels" and the reader not noticing.
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Search intent match | Does the page answer the question actually being asked? |
| 2 | Original value test | What exists here that is not already on ten other sites? |
| 3 | Source and evidence review | Every claim resolves to a ledger entry with a capture date. |
| 4 | Medical review | A named clinician checks claims against their primary sources. |
| 5 | Pricing verification | Figures re-captured from the provider's own page, dated. |
| 6 | Conflict-of-interest review | Any relationship that could bias the page, declared. |
| 7 | Legal and regulatory language | No implied approval, no generic claim, no individual advice. |
| 8 | Accessibility review | WCAG 2.2 AA, keyboard, contrast, chart data tables. |
| 9 | Mobile QA | 390px viewport hides no fee, qualifier, status or date. |
| 10 | Structured-data validation | JSON-LD matches what a reader can see. |
| 11 | Internal-link validation | Parent hub, methodology, siblings, tool or dataset. |
| 12 | Duplication and cannibalisation check | No two pages chasing the same intent. |
| 13 | Date and cadence assignment | Review dates set from real work, not from the calendar. |
| Date | What happened | Effect on compounded access |
|---|---|---|
| 2022 | Tirzepatide added to the FDA drug shortage list | A shortage listing is what permitted compounders to make copies of the approved product. |
| 2024-10 | FDA declared the tirzepatide shortage resolved | Removing the shortage listing removed one of the two legal pathways for compounding tirzepatide. |
| 2025-02 | FDA declared the semaglutide shortage resolved | The same pathway closed for semaglutide four months later. |
| 2025-09-16 | FDA issued 55+ warning letters to online GLP-1 sellers | Letters cited misleading direct-to-consumer advertising of compounded GLP-1 products. |
| 2026-02-09 | Novo Nordisk sued Hims & Hers over compounded semaglutide | Patent infringement claim following the launch of a low-cost compounded oral product. |
| 2026-03-03 | FDA released 30 further warning letters to telehealth firms | Targeting claims that compounded GLP-1s are equivalent to the branded products. |
| 2026-03-09 | Hims & Hers settled with Novo Nordisk and pivoted to branded supply | Hims agreed to offer branded semaglutide and cease most compounded GLP-1 marketing. The largest compounded seller in the category left it. This changes who is actually in the compounded market. |
| 2026-04-30 | FDA proposed excluding tirzepatide from the 503B bulks list | The agency found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk drug substances. This proposal targets the second and last remaining pathway. |
| 2026-05-01 | Formal notice published at 91 Fed. Reg. 23431 | Docket 2026-08552 sets out the agency's substance-by-substance reasoning. |
| 2026-06-26 | Comment period extended to 30 July 2026 | FDA granted an extension after a request for more time to respond. Comments inform, but do not bind, the final determination. |
| 2026-07-30 | Comment period closes | After this date the agency considers submissions before making a final determination. No final determination had published as of 24 July 2026. |
| Requirement | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Compounds pursuant to | A prescription for an identified individual patient | May compound without patient-specific prescriptions |
| FDA registration | Not registered as an outsourcing facility | Registers with FDA |
| CGMP requirements | Not required to meet CGMP | Must comply with CGMP — though registration alone is not evidence of compliance |
| Primary oversight | State board of pharmacy | FDA, on a risk-based inspection schedule |
| Adverse-event reporting | Not required under 503A | Required to report adverse events to FDA |
| Product approval status | Not an FDA-approved product | Not an FDA-approved product |
| What registration establishes | Not applicable | FDA received the required information, nothing more Verified |
Questions readers actually ask
Does NAD+ therapy work?
Human trials of NAD+ precursors reliably raise blood NAD+ levels. They have not reliably produced clinical benefit on hard endpoints.
Is IV NAD+ better than oral?
No trial has demonstrated that raising NAD+ faster or higher produces outcomes oral precursors do not. Oral trials that successfully raised levels largely did not produce benefit.
Is NAD+ regulated as a drug?
NAD+ and its precursors are sold in several regulatory categories depending on formulation and claims. Injectable preparations prepared by a compounding pharmacy require a prescription.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Tirzepatide, Lean Mass and Muscle LossResearch
- Tirzepatide vs Semaglutide: What the Head-to-Head Trial ShowsJournal
- Tirzepatide and Type 2 Diabetes PreventionResearch
- Tirzepatide and Sleep Apnea: Evidence and FDA StatusJournal
- Tirzepatide and PCOS: What Evidence Exists?Research
- Tirzepatide and Heart Failure With Preserved Ejection FractionJournal
- Tirzepatide and Fatty Liver / MASHResearch
Related coverage
GLP-1 Tirzepatide Reviews. “NAD+ Therapy: Strong Biology, Weak Clinical Evidence.” S.J Partners LLC, 2026-07-24. https://glptirzepatidereviews.com/peptides/nad-plus/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.